Ascento-CDA is a healthcare analytics company building a scalable platform for the early detection of dementia and diabetes by identifying biologic activity years before symptoms appear. Dementia and diabetes are among the largest and longest-duration cost drivers in global healthcare, largely because disease is detected too late—after biologic processes are already advanced and expensive to manage.

The company's proprietary analytic engine integrates immunology data, retinal imaging signals, and cognitive assessments to surface early biologic activity that conventional tools miss. These data streams already exist at scale in clinical practice, but are rarely analyzed together. Ascento-CDA transforms them into actionable intelligence that reclassifies hidden risk in patients who are otherwise labeled “low risk,” enabling earlier and more targeted intervention.
The platform is designed to generate value on both sides of the healthcare market. For insurers and payers, early detection enables upstream intervention that reduces lifetime medical costs driven by complications, hospitalizations, and long-term care. For health providers, the same insight unlocks net-new revenue through earlier diagnostics, specialist pathways, and recurring pre-clinical care programs—expanding outpatient utilization without requiring new infrastructure.

Ascento-CDA is built to integrate seamlessly into existing workflows and to operate across fee-for-service and value-based care environments. The model is capital-efficient, software-led, and benefits from strong data defensibility as biologic and longitudinal datasets compound over time.
With early clinical validation underway and engagement across healthcare and commercial stakeholders, Ascento-CDA is positioned to become a category-defining analytics layer for pre-clinical disease detection—aligning payer cost reduction, provider revenue growth, and scalable platform economics.